Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

UCL

- PMLiVE

UK biotech funding falls 40% between 2018 and 2019

Drop attributed to global uncertainty and Neil Woodford scandal

- PMLiVE

EU group calls for ‘targeted actions’ to mitigate impact of Brexit

Committee wants to ensure safe supply of drugs and medical devices

- PMLiVE

EU, US biotechs merge to create fibrosis, cancer player

New company will be headquartered in Copenhagen, Denmark

- PMLiVE

Astellas bulks up immuno-oncology pipeline with $665m Xyphos deal

Closely follows $3bn acquistion of gene therapy specialist Audentes

Bristol Myers Squibb logo

Armed with new data, BMS plans filings for Celgene CAR-T liso-cel

Achieved a 53% complete response rate in study participants

- PMLiVE

Five key trends in precision and personalised healthcare

Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies...

Blue Latitude Health

- PMLiVE

Thousands of EU staffers have left NHS since 2016, says Lib Dems

Figures come from information provided by 50 NHS hospital trusts

- PMLiVE

UK is a leader in early clinical research but falls in later study stages, says ABPI

The UK faces challenges to stay competitive in clinical research globally

- PMLiVE

Launch Excellence 2020

In this special pack, we provide a comprehensive outlook of launch excellence. We cover topics ranging from gathering effective insights, to understanding the current landscape, and the importance of pre-launch...

Blue Latitude Health

- PMLiVE

Precision medicine at Blue Latitude Health

At Blue Latitude Health we have identified 90+ insights about commercialising precision medicines. Check out our video to get a run down on three core components of the commercialisation and...

Blue Latitude Health

- PMLiVE

Personalised medicine can improve treatment, but access still an issue

Barriers to access could harm uptake of potentially transformative therapies

Understanding the evolving CAR-T market

In 2017 the approval of the first CAR-T treatment took the world by storm, transforming the way cancer is treated, but two years later more than 500 CAR-Ts are in...

Blue Latitude Health

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links